Quattro Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Quattro Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5	Closed	-$858	–	276
2025 Q4	$858	Buy	+5	New	+$812	﹤0.01%	448

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Quattro Advisors's IBB Position: Q1 2026 in Review

Quattro Advisors sold out of iShares Biotechnology ETF (IBB) in Q1 2026, closing a stake of 5 shares — an estimated $858 sold.

Quattro Advisors first reported a position in IBB in Q4 2025 and held it in 1 quarter. The position peaked at $858 in Q4 2025. 921 funds tracked by Wall St. Rank hold IBB as of Q1 2026.

Quattro Advisors reported no remaining iShares Biotechnology ETF position as of Q1 2026 after selling out during the quarter.
Quattro Advisors sold 5 iShares Biotechnology ETF shares in Q1 2026, an estimated $858.
Quattro Advisors first reported a position in iShares Biotechnology ETF in Q4 2025 and held it in 1 quarter.
Quattro Advisors's iShares Biotechnology ETF position peaked at $858 in Q4 2025.
921 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2026.

Based on Quattro Advisors's 13F filing for Q1 2026, filed 15 May 2026.